Procter & Gamble Health Limited
NSE: PGHL BSE: PGHL
Prev Close
5935
Open Price
5935
Volume
41,877
Today Low / High
5917 / 6100
52 WK Low / High
4863 / 6175.5
Range
5,650 - 6,244
Prev Close
5942.1
Open Price
5942.1
Volume
2,574
Today Low / High
5918.6 / 6100
52 WK Low / High
4912.3 / 6107.55
Range
5,653 - 6,248
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 5947 (target range: 5,650 - 6,244), reflecting a change of 12 (0.20219%). On the BSE, it is listed at 5950.15 (target range: 5,653 - 6,248), showing a change of 8.05 (0.13547%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Procter & Gamble Health Limited Graph
Procter & Gamble Health Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Procter & Gamble Health Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 5,947.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 5,950.15 | 6,009.65 | 5,408.69 - 6,610.62 |
6,069.15 | 4,855.32 - 7,282.98 | ||
6,128.65 | 4,290.06 - 7,967.25 | ||
Bearish Scenario | 5,950.15 | 5,890.65 | 5,301.58 - 6,479.71 |
5,831.15 | 4,664.92 - 6,997.38 | ||
5,771.65 | 4,040.15 - 7,503.14 |
Overview of Procter & Gamble Health Limited
ISIN
INE199A01012
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
10,003
Market Cap
98,766,430,000
Last Dividend
160
Official Website
IPO Date
2002-07-01
DCF Diff
-2,216.66
DCF
8,152
Financial Ratios Every Investor Needs
Stock Dividend of PGHL
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2025-08-22 | August 22, 25 | 45 | 45 | 2025-08-22 | 2025-09-25 | |
2025-02-21 | February 21, 25 | 80 | 80 | 2025-02-21 | 2025-03-07 | |
2024-11-28 | November 28, 24 | 60 | 60 | 2024-11-28 | 2024-12-25 | |
2024-02-14 | February 14, 24 | 200 | 200 | 2024-02-14 | 2024-03-03 | |
2023-11-23 | November 23, 23 | 50 | 50 | 2023-11-23 | 2023-12-30 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-06-30 | 1,151.26 Cr | 330.56 Cr | 820.70 Cr | 0.7129 | 0.00 Cr | 0.00 Cr | 606.98 Cr | 200.98 Cr | 121.07 | 307.44 Cr | 0.1746 |
2023-06-30 | 1,229.62 Cr | 361.84 Cr | 867.78 Cr | 0.7057 | 5.71 Cr | 148.17 Cr | 314.24 Cr | 229.47 Cr | 138.24 | 342.72 Cr | 0.1866 |
2022-06-30 | 1,092.04 Cr | 367.11 Cr | 724.93 Cr | 0.6638 | 6.55 Cr | 23.32 Cr | 260.31 Cr | 192.52 Cr | 115.98 | 280.52 Cr | 0.1763 |
2021-06-30 | 990.79 Cr | 339.27 Cr | 651.52 Cr | 0.6576 | 3.93 Cr | 47.43 Cr | 234.98 Cr | 176.80 Cr | 106.51 | 263.77 Cr | 0.1784 |
2020-06-30 | 903.38 Cr | 501.63 Cr | 401.76 Cr | 0.4447 | 5.73 Cr | 72.83 Cr | 196.84 Cr | 169.39 Cr | 102.04 | 208.80 Cr | 0.1875 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-06-30 | 244.36 Cr | 794.36 Cr | 256.12 Cr | 538.2400 Cr | 9.56 Cr | -234.80 Cr | 109.11 Cr | 131.53 Cr | 0.00 Cr | 0.00 Cr | 11.64 Cr | 218.9100 Cr |
2023-06-30 | 435.05 Cr | 1,101.19 Cr | 350.30 Cr | 750.8900 Cr | 12.00 Cr | -423.05 Cr | 134.94 Cr | 173.27 Cr | 54.82 Cr | 0.00 Cr | -12.64 Cr | 303.9000 Cr |
2022-06-30 | 319.40 Cr | 893.72 Cr | 277.23 Cr | 616.4900 Cr | 2.83 Cr | -316.57 Cr | 115.21 Cr | 149.62 Cr | 0.56 Cr | 0.00 Cr | -3.83 Cr | 235.8300 Cr |
2021-06-30 | 464.05 Cr | 986.16 Cr | 282.45 Cr | 703.7100 Cr | 7.61 Cr | -456.44 Cr | 118.37 Cr | 140.13 Cr | 97.22 Cr | 0.00 Cr | -2.66 Cr | 238.9700 Cr |
2020-06-30 | 639.09 Cr | 1,176.38 Cr | 270.04 Cr | 906.3400 Cr | 0.00 Cr | -639.09 Cr | 136.00 Cr | 119.42 Cr | 1.10 Cr | 0.00 Cr | 3.37 Cr | 227.3400 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-06-30 | 228.2800 Cr | -6.8700 Cr | -418.1100 Cr | 206.5600 Cr | -196.6900 Cr | 238.7300 Cr | -21.7300 Cr | 200.9800 Cr | 0.0000 Cr | -414.9900 Cr | 23.1300 Cr |
2023-06-30 | 236.0000 Cr | -21.5000 Cr | -98.4700 Cr | 193.5200 Cr | 116.0200 Cr | 435.4200 Cr | -42.4800 Cr | 314.2000 Cr | 0.0000 Cr | -93.7900 Cr | -32.3900 Cr |
2022-06-30 | 169.5200 Cr | -25.5400 Cr | -288.6300 Cr | 131.6000 Cr | -144.6500 Cr | 319.4000 Cr | -37.9200 Cr | 253.3700 Cr | 0.0000 Cr | -283.8500 Cr | -2.0200 Cr |
2021-06-30 | 247.2600 Cr | -32.2700 Cr | -386.6300 Cr | 194.6800 Cr | -171.6400 Cr | 464.0500 Cr | -52.5800 Cr | 233.2800 Cr | 0.0000 Cr | -381.7800 Cr | 15.2600 Cr |
2020-06-30 | 295.9300 Cr | 104.0800 Cr | -883.4100 Cr | 272.6600 Cr | -480.5200 Cr | 639.0900 Cr | -23.2700 Cr | 169.3875 Cr | 0.0000 Cr | -883.4100 Cr | -20.7500 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 310.99 Cr | 98.72 Cr | 212.27 Cr | 0.6826 | 75.55 Cr | 61.18 Cr | 36.86 | 84.03 Cr | 0.1967 |
2024-12-31 | 309.77 Cr | 75.73 Cr | 234.04 Cr | 0.7555 | 117.88 Cr | 90.90 Cr | 54.76 | 127.39 Cr | 0.2934 |
2024-09-30 | 313.41 Cr | 140.04 Cr | 173.37 Cr | 0.5532 | 108.27 Cr | 82.33 Cr | 49.60 | 117.32 Cr | 0.2627 |
2024-06-30 | 283.88 Cr | 134.96 Cr | 148.92 Cr | 0.5246 | 41.09 Cr | 16.78 Cr | 10.11 | 30.19 Cr | 0.0591 |
2024-03-31 | 252.48 Cr | 126.57 Cr | 125.91 Cr | 0.4987 | 63.19 Cr | 46.56 Cr | 28.05 | 70.03 Cr | 0.1844 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 182.08 Cr | 23.98 Cr | 206.06 Cr | 146.99 Cr | 109.37 Cr | 526.39 Cr | 121.99 Cr | 794.20 Cr | 257.24 Cr |
2024-12-31 | 266.43 Cr | 25.83 Cr | 292.26 Cr | 132.24 Cr | 118.78 Cr | 612.49 Cr | 125.27 Cr | 870.15 Cr | 259.69 Cr |
2024-09-30 | 0.00 Cr | 0.00 Cr | 244.36 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -538.24 Cr |
2024-06-30 | 244.36 Cr | 0.00 Cr | 244.36 Cr | 85.33 Cr | 109.11 Cr | 524.22 Cr | 131.53 Cr | 794.36 Cr | 256.12 Cr |
2024-03-31 | -425.56 Cr | 851.12 Cr | 425.56 Cr | 0.00 Cr | 0.00 Cr | 425.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 78.53 Cr | 49.22 Cr | -0.05 Cr | -133.58 Cr | -84.41 Cr | 182.27 Cr | 266.68 Cr | -3.23 Cr | 45.99 Cr |
2024-12-31 | 90.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | 82.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | 16.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 46.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,733.80 | ₹4,159,871,664,000.00 | ₹2,318,664.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,650.00 | ₹1,765,368,850,000.00 | ₹226,973.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,730.60 | ₹1,262,602,917,000.00 | ₹439,520.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,292.10 | ₹1,075,456,274,108.00 | ₹1,386,961.00 |
Mankind Pharma Limited | MANKIND | ₹2,575.50 | ₹1,062,982,921,380.00 | ₹763,328.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹995.15 | ₹1,001,349,784,500.00 | ₹775,382.00 |
Lupin Limited | LUPIN | ₹1,984.60 | ₹906,460,096,200.00 | ₹754,124.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,158.00 | ₹672,568,716,000.00 | ₹672,249.00 |
Alkem Laboratories Limited | ALKEM | ₹5,099.60 | ₹609,733,674,000.00 | ₹69,765.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,153.60 | ₹607,748,073,600.00 | ₹786,090.00 |
Laurus Labs Limited | LAURUSLABS | ₹881.45 | ₹475,603,095,050.00 | ₹5,551,173.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,529.50 | ₹388,040,268,000.00 | ₹501,348.00 |
Cohance Lifesciences Limited | COHANCE | ₹997.40 | ₹381,572,333,779.00 | ₹30,739.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,800.50 | ₹349,816,056,000.00 | ₹68,739.00 |
Piramal Enterprises Limited | PEL | ₹1,287.60 | ₹291,870,592,800.00 | ₹4,377,271.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,782.60 | ₹278,652,466,800.00 | ₹198,162.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,684.80 | ₹273,744,619,200.00 | ₹253,355.00 |
Eris Lifesciences Limited | ERIS | ₹1,816.60 | ₹247,415,470,200.00 | ₹258,998.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,340.00 | ₹233,500,000,000.00 | ₹39,783.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹1,007.60 | ₹198,056,878,800.00 | ₹43,245.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,236.30 | ₹196,919,100,300.00 | ₹1,978,762.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹13,910.00 | ₹178,463,909,000.00 | ₹72,265.00 |
NATCO Pharma Limited | NATCOPHARM | ₹973.15 | ₹174,300,896,500.00 | ₹709,365.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,145.80 | ₹163,105,905,860.00 | ₹121,630.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹492.15 | ₹119,417,244,600.00 | ₹954,418.00 |
Procter & Gamble Health Limited | PGHL | ₹5,947.00 | ₹98,716,631,800.00 | ₹41,877.00 |
Shilpa Medicare Limited | SHILPAMED | ₹919.15 | ₹89,884,505,735.00 | ₹41,687.00 |
Strides Pharma Science Limited | STAR | ₹945.35 | ₹87,126,008,445.00 | ₹401,712.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹946.50 | ₹85,785,667,830.00 | ₹174,284.00 |
FDC Limited | FDC | ₹484.45 | ₹78,873,304,500.00 | ₹30,593.00 |
Suven Life Sciences Limited | SUVEN | ₹269.30 | ₹58,727,328,200.00 | ₹85,394.00 |
Innova Captab Limited | INNOVACAP | ₹917.50 | ₹52,503,873,275.00 | ₹36,415.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹151.93 | ₹49,304,627,460.00 | ₹195,988.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹522.25 | ₹47,665,757,500.00 | ₹446,949.00 |
Sequent Scientific Limited | SEQUENT | ₹175.86 | ₹44,023,913,100.00 | ₹235,318.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹619.85 | ₹43,641,035,130.00 | ₹39,695.00 |
Hikal Limited | HIKAL | ₹329.80 | ₹40,664,669,800.00 | ₹316,649.00 |
Gufic Biosciences Limited | GUFICBIO | ₹404.55 | ₹40,567,464,900.00 | ₹352,761.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,405.80 | ₹39,789,526,200.00 | ₹52,499.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹705.15 | ₹35,764,573,365.00 | ₹37,012.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹59.69 | ₹32,707,374,260.00 | ₹1,444,289.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹651.90 | ₹31,390,940,700.00 | ₹124,331.00 |
Indoco Remedies Limited | INDOCO | ₹324.50 | ₹29,934,443,550.00 | ₹64,322.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹100.29 | ₹29,437,822,830.00 | ₹15,953,556.00 |
Alembic Limited | ALEMBICLTD | ₹114.24 | ₹29,334,775,566.00 | ₹212,418.00 |
Key Executives
Gender: female
Year Born:
Gender: female
Year Born:
Gender: male
Year Born: 1987
Gender: male
Year Born: 1969
FAQs about Procter & Gamble Health Limited
The CEO is Milind Vasant Thatte.
The current price is ₹5,950.00.
The range is ₹4863-6175.5.
The market capitalization is ₹9,876.64 crores.
The dividend yield is 2.35%.
The P/E ratio is 39.32.
The company operates in the Healthcare sector.
Overview of Procter & Gamble Health Limited (ISIN: INE199A01012) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹9,876.64 crores and an average daily volume of 10,003 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹160.